RenovoRx to Participate at the Canaccord Genuity MedTech Diagnostics and Digital Health & Services Forum
RenovoRx Advances TAMP into Borderline Resectable Pancreatic Cancer with First Patient Enrolled in Investigator-Initiated PRISM-TAMP Trial
RenovoRx Announces Peer-Reviewed Publication Highlighting the TAMP Platform's Potential to Improve Chemotherapeutic Delivery for Locally Advanced Pancreatic Cancer
RenovoRx Highlights Peer-Reviewed Publication of Pharmacokinetic and Pharmacodynamic Data Supporting TAMP Platform's Targeted Drug-Delivery in Locally Advanced Pancreatic Cancer
RenovoRx Receives Notice of Allowance for New U.S. Patent Covering RenovoCath®, an Advanced Dual-Occlusion Catheter, for Targeted Therapeutic Drug-Delivery for Cancer Treatment
RenovoRx Reports Record Second Quarter 2026 Results, Driven by Accelerating Commercial Adoption and 61% Sequential Quarterly Revenue Growth
RenovoRx Achieves Major Milestone with Full Enrollment in Phase III TIGeR-PaC Trial for Locally Advanced Pancreatic Cancer
RenovoRx Announces First Commercial Clinical Use of RenovoCath® in Sarcoma Patient Treatment, Marking Expansion of Targeted Drug-Delivery Device to Other Solid Tumors
RenovoRx to Highlight TAMP Platform at JonesTrading Virtual Key Opinion Leader Webinar on the Evolving Pancreatic Cancer Landscape, August 13th
RenovoRx to Host Second Quarter 2026 Financial Results and Business Highlights Conference Call on August 12th at 4:30 p.m. ET
Michael Gentile Announces Filing of Early Warning Report Related to Acquisition of Common Shares of Cascadia Minerals Ltd.